BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1232 related articles for article (PubMed ID: 19509327)

  • 1. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
    Weisman MH
    J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of infections with biologic therapies for rheumatoid arthritis.
    Furst DE
    Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficacies: antimalarials to abatacept - the choice is ours.
    Russell AS
    J Rheumatol Suppl; 2009 Jun; 82():17-24. PubMed ID: 19509326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapeutics for rheumatoid arthritis.
    Bingham CO
    Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
    CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.
    Keystone EC
    J Rheumatol; 2011 Aug; 38(8):1552-62. PubMed ID: 21572154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept as add-on therapy for rheumatoid arthritis.
    Allison C
    Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of biologics in rheumatoid arthritis: where are we going?
    Pucino F; Harbus PT; Goldbach-Mansky R
    Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S19-41. PubMed ID: 16960244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on biologics in juvenile idiopathic arthritis.
    Ilowite NT
    Curr Opin Rheumatol; 2008 Sep; 20(5):613-8. PubMed ID: 18698187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
    Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143
    [No Abstract]   [Full Text] [Related]  

  • 19. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
    Barr C
    J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
    Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
    Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.